Literature DB >> 27242315

Resurrection of response-guided therapy for sofosbuvir combination therapies.

Harel Dahari1, Phillippe Halfon2, Scott J Cotler3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27242315      PMCID： PMC5072361          DOI： 10.1016/j.jhep.2016.05.028

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  19 in total

1.  Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.

Authors:  Patrick R Harrington; Damon J Deming; Takashi E Komatsu; Lisa K Naeger
Journal:  Clin Infect Dis       Date:  2015-05-22       Impact factor: 9.079

Review 2.  New hepatitis C therapies: the toolbox, strategies, and challenges.

Authors:  Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2014-03-12       Impact factor: 22.682

3.  Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.

Authors:  Harel Dahari; Shimon Shteingart; Inna Gafanovich; Scott J Cotler; Massimo D'Amato; Ralf T Pohl; Gali Weiss; Yaakov J Ashkenazi; Thomas Tichler; Eran Goldin; Yoav Lurie
Journal:  Liver Int       Date:  2014-10-10       Impact factor: 5.828

4.  Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.

Authors:  Harel Dahari; Jeremie Guedj; Alan S Perelson; Thomas J Layden
Journal:  Curr Hepat Rep       Date:  2011-07-02

5.  Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

Authors:  Ira M Jacobson; Gregory J Dore; Graham R Foster; Michael W Fried; Monica Radu; Vladimir V Rafalsky; Larysa Moroz; Antonio Craxi; Monika Peeters; Oliver Lenz; Sivi Ouwerkerk-Mahadevan; Guy De La Rosa; Ronald Kalmeijer; Jane Scott; Rekha Sinha; Maria Beumont-Mauviel
Journal:  Lancet       Date:  2014-06-04       Impact factor: 79.321

6.  Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.

Authors:  Michael W Fried; Stephanos J Hadziyannis; Mitchell L Shiffman; Diethelm Messinger; Stefan Zeuzem
Journal:  J Hepatol       Date:  2010-11-23       Impact factor: 25.083

7.  Evaluation of the COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study.

Authors:  Harald H Kessler; Bryan R Cobb; Heiner Wedemeyer; Benjamin Maasoumy; Veronique Michel-Treil; Luca Ceccherini-Nelli; Birgit Bremer; Margit Hübner; Anna Helander; Hacene Khiri; Gabrielle Heilek; Christian O Simon; Kevin Luk; Shagufta Aslam; Philippe Halfon
Journal:  J Clin Virol       Date:  2015-03-31       Impact factor: 3.168

8.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

9.  Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.

Authors:  Peter Ferenci; Hermann Laferl; Thomas-Matthias Scherzer; Michael Gschwantler; Andreas Maieron; Harald Brunner; Rudolf Stauber; Martin Bischof; Bernhard Bauer; Christian Datz; Karin Löschenberger; Elisabeth Formann; Katharina Staufer; Petra Steindl-Munda
Journal:  Gastroenterology       Date:  2008-05-27       Impact factor: 22.682

10.  Sustained Virologic Response for Chronic Hepatitis C Infection after 27 Days of Treatment with Sofosbuvir and Ribavirin.

Authors:  Eric G Meissner; Amy Nelson; Miriam Marti; Henry Masur; Anu Osinusi; Shyam Kottilil
Journal:  Open Forum Infect Dis       Date:  2014       Impact factor: 3.835
View more
  3 in total

1.  Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.

Authors:  Martina Gambato; Laetitia Canini; Sabela Lens; Frederik Graw; Elena Perpiñan; Maria-Carlota Londoño; Susan L Uprichard; Zoe Mariño; Enric Reverter; Concepcio Bartres; Patricia González; Anna Pla; Josep Costa; Patrizia Burra; Scott J Cotler; Xavier Forns; Harel Dahari
Journal:  Liver Int       Date:  2018-12-28       Impact factor: 5.828

2.  HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.

Authors:  Laetitia Canini; Michio Imamura; Yoshiiku Kawakami; Susan L Uprichard; Scott J Cotler; Harel Dahari; Kazuaki Chayama
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

3.  Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study.

Authors:  Ohad Etzion; Harel Dahari; David Yardeni; Assaf Issachar; Anat Nevo-Shor; Michal Cohen-Naftaly; Yaffa Ashur; Susan L Uprichard; Orly Sneh Arbib; Daniela Munteanu; Marius Braun; Scott J Cotler; Naim Abufreha; Ayelet Keren-Naus; Yonat Shemer-Avni; Orna Mor; Jayanah Murad; Victor Novack; Amir Shlomai
Journal:  Sci Rep       Date:  2020-10-20       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.